..0001) largely related to significant BMC improvement in the cortical compartment (p<0.0001). These results supplement the data from DXA on the positive effect of denosumab on BMD in both the cortical and trabecular compartments...

Effect of denosumab treatment on the risk of fractures in subgroups of women with postmenopausal osteoporosis

..More information about the effectiveness of denosumab in reducing fracture risk, its tolerability and safety, and the response to discontinuing therapy will be provided by ongoing clinical studies...

Efficacy and safety of monthly oral ibandronate in the prevention of postmenopausal bone loss

..We conclude that patients can be switched from oral ALN to ZOL 5 mg infusion with maintenance of therapeutic effect for at least 12 months and that patients prefer a once yearly infusion to weekly oral therapy...

..This review highlights the effects of parathyroid hormone on bone density and fracture risk in patients with osteoporosis and addresses several of the important issues pertaining to the use of these new agents in daily clinical practice...

..Having these effective agents challenges clinicians to identify the most appropriate patients for bisphosphonate use and to develop strategies to improve acceptance of and adherence to these useful agents...

A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density

..For elderly patients, the use of hip protectors may be used as a treatment of last resort. Regardless of the age of the patient, individual patient risk factors must be considered to target appropriate treatment and prevent fracture...

How does raloxifene reduce fracture risk?

Michael R McClungMenopause 9:306-8. 2002

Assessment of mortality in patients enrolled in a risedronate clinical trial program: a retrospective cohort study

..At present, concurrent therapy with antiresorptive therapy, particularly bisphosphonates, should be avoided, although sequential therapy with such agents may consolidate the beneficial effects upon the skeleton after PTH is discontinued...

Bisphosphonates and osteonecrosis of the jaw

Nelson B WattsAnn Intern Med 145:791-2; author reply 792. 2006

Looking for answers in all the wrong places

Michael R McClungMenopause 14:7-9. 2007

Official positions of the international society for clinical densitometry

..Recommendations that are accepted become the Official Positions of the ISCD. This Special Report summarizes the methodology of the ISCD Position Development Conferences and presents selected Official Positions of general interest...